Ildiko Lingvay, M.D. Professor School Medical School Department Internal Medicine | Public Health You have reached the Academic Profile. For more information on the doctor and patient care, please visit the clinical profile. Biography Ildiko Lingvay, M.D., M.P.H., M.S.C.S., is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of the Division of Endocrinology. She holds a secondary appointment in the Peter O'Donnell Jr. School of Public Health. Originally from Bucharest, Romania, Dr. Lingvay earned her medical degree with honors at the Carol Davila University of Medicine and Pharmacy in Bucharest. She completed internal medicine residency training at Texas Tech University School of Medicine in Lubbock, Texas, followed by a fellowship in endocrinology, diabetes, and metabolism at UT Southwestern. She holds a master's degree in public health from the UT Houston School of Public Health, as well as a master's degree in clinical science with distinction from UT Southwestern. Certified by the American Board of Internal Medicine in endocrinology and the American Board of Obesity Medicine, Dr. Lingvay joined the UT Southwestern faculty in 2005. Dr. Lingvay is a clinical investigator in the field of diabetes, obesity, and associated metabolic complications. She leads an active clinical research program in the Division of Endocrinology. In 2007 she received a National Institutes of Health Career Development Award to study the role of pancreatic triglyceride accumulation in beta-cell failure and type 2 diabetes and to further develop her career as a clinical investigator. She has published her work in an array of peer-reviewed journals, such as the Journal of the American Medical Association, New England Journal of Medicine, Circulation, JAMA Internal Medicine, Diabetes Care, and The Lancet. She has also contributed to many textbooks in the field of diabetes and is on the editorial board of several journals. Dr. Lingvay has been invited to present lectures to her peers throughout the United States and around the world. She is an active member of the American Diabetes Association, which she has served as a member of several different committees. Education Medical School Carol Davila University of Medicine & Pharmacy (1998) Internship/Residency Texas Tech University Health Sciences Center (2002), Internal Medicine Fellowship UT Southwestern Medical Center (2005), Endocrinology & Metabolism Other Post Graduate Training University of Texas Health Science Center at Houston (2006) Graduate School University of Texas Health Science Center at Houston (2006), Public Health Other Post Graduate Training UT Southwestern Medical Center (2008) Graduate School UT Southwestern Medical Center (2008), Clinical Research Research Interest Metabolic Syndrome Nonalcoholic Fatty Liver Disease (NAFLD) Nonalcoholic Steatohepatitis (NASH) Obesity Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus Publications Featured Publications Pharmacotherapies for Post-Bariatric Weight Regain: Real-World Comparative Outcomes. Gazda CL, Clark JD, Lingvay I, Almandoz JP, Obesity (Silver Spring) 2021 May 29 5 829-836 Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I, Lancet 2021 Mar 397 10278 971-984 Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study. Lingvay I, Kirk AR, Lophaven S, Wolden ML, Shubrook JH, Diabetes Ther 2021 Feb Once-Weekly Semaglutide in Adults with Overweight or Obesity. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, N Engl J Med 2021 Feb Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance. Almandoz JP, Lingvay I, Morales J, Campos C, Clin Diabetes 2020 Oct 38 4 390-402 Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. Ryan DH, Lingvay I, Colhoun HM, Deanfield J, Emerson SS, Kahn SE, Kushner RF, Marso S, Plutzky J, Brown-Frandsen K, Gronning MOL, Hovingh GK, Holst AG, Ravn H, Lincoff AM, Am. Heart J. 2020 Jul 229 61-69 Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. Doria A, Galecki AT, Spino C, Pop-Busui R, Cherney DZ, Lingvay I, Parsa A, Rossing P, Sigal RJ, Afkarian M, Aronson R, Caramori ML, Crandall JP, de Boer IH, Elliott TG, Goldfine AB, Haw JS, Hirsch IB, Karger AB, Maahs DM, McGill JB, Molitch ME, Perkins BA, Polsky S, Pragnell M, Robiner WN, Rosas SE, Senior P, Tuttle KR, Umpierrez GE, Wallia A, Weinstock RS, Wu C, Mauer M, N. Engl. J. Med. 2020 06 382 26 2493-2503 Roux-en-Y Gastric Bypass Compared to Equivalent Diet Restriction: Mechanistic Insights into Diabetes Remission. Pop LM, Mari A, Zhao TJ, Mitchell L, Burgess S, Li X, Adams-Huet B, Lingvay I Diabetes Obes Metab 2018 Mar Hyposialylated IgG activates endothelial IgG receptor Fc?RIIB to promote obesity-induced insulin resistance. Tanigaki K, Sacharidou A, Peng J, Chambliss KL, Yuhanna IS, Ghosh D, Ahmed M, Szalai AJ, Vongpatanasin W, Mattrey RF, Chen Q, Azadi P, Lingvay I, Botto M, Holland WL, Kohler JJ, Sirsi SR, Hoyt K, Shaul PW, Mineo C J. Clin. Invest. 2017 Nov Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T N. Engl. J. Med. 2016 Sep Results 1-10 of 70 1 2 3 4 5 Next Last Books Featured Books Diabetes in Diseases of Exocrine Pancreas. In Atypical Diabetes: Pathophysiology, Clinical Presentations, and Treatment Options Gunasakaran U, Xamaropulous X, Jessica A, Tumyan A, Lingvay I (2018). American Diabetes Association Inpatient Diabetes Management post-Bariatric Surgery. In Managing Diabetes and Hyperglycemia in the Hospital Setting: A Clinician's Guide Alexanian S, Lingvay I (2016). American Diabetes Association Management of Surgery and Anesthesia. In Therapy for Diabetes Mellitus and Related Disorders Lingvay I, Aviles-Santa LM, Raskin P (2009). American Diabetes Association Case 16: Misclassification of MODY 3 as Type 1. In Atypical Diabetes: Pathophysiology, Clinical Presentations, and Treatment Options Song L, McNulty JN, Lingvay I (2018). American Diabetes Association The Thyroid. In Textbook of Endocrine Physiology Lingvay I, Holt S (2012). Oxford University Press Inc Secondary Forms of Diabetes Mellitus. In American College of Physicians- Medicine Lingvay I, Raskin P (2006). American College of Physicians Non-insulin Pharmacological Therapies. In Type 2 Diabetes Mellitus: An Evidence-Based Approach to Practical Management Lingvay I, Rhee C, Raskin P (2006). Honors & Awards Jean W. Wilson Award for Scientific Mentorship (2019) Jean W. Wilson Award for Scientific Mentorship (2015) Jean W. Wilson Award for Scientific Mentorship (2011) Professional Associations/Affiliations American Diabetes Association American Federation for Medical Research European Association for the Study of Diabetes The Endocrine Society
